Table 3.
Baseline |
12 mo |
Change |
|||||
---|---|---|---|---|---|---|---|
P1 | P2 | P3a | P2 | P3a | P2 | P3 | |
DXA | |||||||
Age, y | 19 | 14 | 10 | 15 | 11 | ||
Height SDS | −3.8 | −2.9 | −2.9 | −3.0 | −2.5 | −1 | +0.4 |
Whole body minus head | |||||||
BMD, g/cm2 | 0.764 | 0.652 | 0.569 | 0.716 | 0.646 | 9.9% | 13.6% |
z Score | −2.9 | −3.6 | −2.5 | −3.2 | −1.8 | +0.4 | +0.7 |
HA z score | −0.5 | −2.5 | −0.7 | −2.2 | −0.1 | +0.3 | +0.6 |
Lumbar spine | |||||||
BMD, g/cm2 | 0.749 | 0.504 | 0.497 | 0.531 | 0.561 | 5.4% | 12.9% |
z Score | −2.7 | −3.2 | −1.6 | −3.9 | −1.0 | −0.7 | +0.6 |
HA z score | −1 | −1.3 | −0.1 | −1.9 | 0.3 | −0.6 | +0.4 |
Total hip | |||||||
BMD, g/cm2 | 0.726 | 0.567 | 0.593 | 0.600 | 0.629 | 5.9% | 6.1% |
z Score | −1.8 | −3.8 | −2.1 | −3.5 | −2.0 | +0.3 | +0.1 |
HA z score | −0.03 | −1.6 | −0.5 | −2.0 | −0.4 | −0.4 | +0.1 |
Forearm | |||||||
BMD, g/cm2 | 0.627 | 0.499 | 0.448 | 0.538 | 0.486 | 7.6% | 8.5% |
z Score | −1.1 | −2.8 | −1.9 | −2.8 | −1.3 | 0 | +0.6 |
HA z score | 0 | −1.7 | −0.5 | −1.8 | 0 | −0.1 | +0.5 |
Total lean body mass, g | 23092 | 27286 | 15274 | 32964 | 18961 | 20.8% | 24.1% |
Total fat mass, g | 17809 | 27380 | 6543 | 26969 | 7390 | −1.5% | 12.9% |
Total body fat % | 42.3 | 49.2 | 29 | 44.2 | 27.1 | −5 | −1.9 |
Bone markers | |||||||
C-telopeptides, ng/mL | 726 | 1974 | 1744 | 1855 | 2262 | −6% | 29% |
Osteocalcin, ng/mL | 28 | 101 | 86 | 138 | 123 | 38% | 43% |
Abbreviation: HA, height-adjusted.
Patient treated with rhIGF-1.